Biotech Analyst Zelin discusses JANX007 (Janux Therapeutics (JANX)) and the evolving prostate cancer landscape on an Analyst/Industry conference call to be held on October 21 at 2 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics Announces Departure of Chief Strategy Officer
- Janux Therapeutics initiated with an Overweight at Barclays
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Janux Therapeutics initiated with a Buy at Truist
- Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements